Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 1, pp 44–55 | Cite as

Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials

  • Dominick J. AngiolilloEmail author
  • David J. Schneider
  • Deepak L. Bhatt
  • William J. French
  • Matthew J. Price
  • Jorge F. Saucedo
  • Tamaz Shaburishvili
  • Kurt Huber
  • Jayne Prats
  • Tiepu Liu
  • Robert A. Harrington
  • Richard C. Becker


Cangrelor is an intravenous antagonist of the P2Y12 receptor characterized by rapid, potent, predictable, and reversible platelet inhibition. However, cangrelor was not superior to clopidogrel in reducing the incidence of ischemic events in the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. A prospectively designed platelet function substudy was performed in a selected cohort of patients to provide insight into the pharmacodynamic effects of cangrelor, particularly in regard to whether cangrelor therapy may interfere with the inhibitory effects of clopidogrel. This pre-defined substudy was conducted in a subset of patients from the CHAMPION-PCI trial (n = 230) comparing cangrelor with 600 mg of clopidogrel administered before percutaneous coronary intervention (PCI) and from the CHAMPION-PLATFORM trial (n = 4) comparing cangrelor at the time of PCI and 600 mg clopidogrel given after the PCI. Pharmacodynamic measures included P2Y12 reaction units (PRU) assessed by VerifyNow P2Y12 testing (primary endpoint marker), platelet aggregation by light transmittance aggregometry following 5 and 20 μmol/L adenosine diphosphate stimuli, and markers of platelet activation determined by flow cytometry. The primary endpoint was the percentage of patients who achieved <20 % change in PRU between baseline and >10 h after PCI. The main trial was stopped early limiting enrollment in the platelet substudy. A total of 167 patients had valid pharmacodynamic assessments for the primary endpoint. The percent of individuals achieving <20 % change in PRU between baseline and >10 h after PCI was higher with cangrelor + clopidogrel (32/84, 38.1 %) compared with placebo + clopidogrel (21/83, 25.3 %), but this was not statistically significant (difference:12.79 %, 95 % CI: −1.18 %, 26.77 %;p = 0.076). All pharmacodynamic markers as well as the prevalence of patients with high on-treatment platelet reactivity were significantly lower in patients treated with cangrelor. A rapid platelet inhibitory effect was achieved during cangrelor infusion and a rapid offset of action after treatment discontinuation. This CHAMPION platelet function substudy represents the largest pharmacodynamic experience with cangrelor, demonstrating its potent P2Y12 receptor inhibitory effects, and rapid onset/offset of action. Although there was no significant pharmacodynamic interaction when transitioning to clopidogrel therapy, further studies are warranted given that enrollment in this study was limited due to premature interruption of the main trial.


Platelet function PCI Clopidogrel Cangrelor 



Funding: This work was supported by The Medicines Company.


Dominick J. Angiolillo reports receiving: honoraria for lectures from Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc; Astra Zeneca; Abbott Vascular; consulting fees from Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company; Portola; Novartis; Medicure; Accumetrics; Arena Pharmaceuticals; Astra Zeneca; Merck; research grants from Bristol Myers Squibb; Sanofi-Aventis; GlaxoSmithKline; Otsuka; Eli Lilly Co; Daiichi Sankyo, Inc., The Medicines Company; Portola; Accumetrics; Schering-Plough; Astra-Zeneca; Eisai. David J. Schneider reports receiving honoraria and research grants from Bristol Myers Squibb; Sanofi-Aventis; The Medicines Company; Johnson & Johnson; Bayer Pharmaceuticals. Deepak L. Bhatt reports receiving: research grants (all significant) from Astra Zeneca, Bristol-Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company. William J. French reports receiving: honoraria for lectures from Sanofi-Aventis and Eli Lilly Co; consulting fees from The Medicines Company and Portola; and research grants from Eli Lilly Co; Daiichi Sankyo, Inc., The Medicines Company, Portola and Schering-Plough. Matthew J. Price reports receiving received consulting fees and honoraria from The Medicines Company, AstraZeneca, Daiichi-Sankyo/Eli Lily & Co, Accumetrics, Bristol-Myers Squibb/sanofi aventis, and Medicure; honoraria for lectures from the Medicines Company and Daiichi-Sankyo/Eli Lily & Co.; and research grants from Accumetrics and Bristol-Myers Squibb/sanofi aventis. Jorge Saucedo reports receiving: honoraria for lectures from Eli Lilly Co; Daiichi Sankyo, Inc; and Merck; consulting fees; Eli Lilly Co; Daiichi Sankyo, Inc.; Medicure; Merck; research grants from Eli Lilly Co; Daiichi Sankyo, Inc., The Medicines Company; Accumetrics; Schering-Plough. Tamaz Shaburishvili reports receiving: consulting fees from New England Research Institute, The Medicines Company. Kurt Huber reports receiving: honoraria for lectures from AstraZenecaM; Bayer Austira; Boehringer-Ingelheim; Eli Lilly Co; Daiichi Sankyo, Inc; Sanofi-Aventis; The Medicines Company. Jayne Prats is an employee of The Medicines Company. Tiepu Liu is an employee of The Medicines Company. Robert A. Harrington reports receiving: research funding to the DCRI from The Medicines Company, Eli Lilly, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers-Squibb, Portola, Novartis, Merck, and AstraZeneca. Consulting fees from AstraZeneca, Sanofi-aventis, BMS, Novartis, and Merck. Full disclosure of all relationships with industry are available at Richard C. Becker reports receiving: research grants from The Medicines Company, AstraZeneca, Johnson and Johnson,Bayer, and Regado Biosciences.Scientific advisory boards and honoraria from Daiich-Sankyo, Regado Biosciences, Boehringer Ingelheim, Merck, and Bristol-Myers-Squibb.


  1. 1.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK (2011) American college of cardiology foundation; American heart association task force on practice guidelines; society for cardiovascular angiography and interventions. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/american heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol 58:e44–e122PubMedCrossRefGoogle Scholar
  2. 2.
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA, Costa MA (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516PubMedCrossRefGoogle Scholar
  3. 3.
    Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R (2010) Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol 56:919–933PubMedCrossRefGoogle Scholar
  4. 4.
    Ferreiro JL, Sibbing D, Angiolillo DJ (2010) Platelet function testing and risk of bleeding complications. Thromb Haemost 103:1128–1135PubMedCrossRefGoogle Scholar
  5. 5.
    Sibbing D, Steinhubl SR, Schulz S, Schömig A, Kastrati A (2010) Platelet aggregation and its association with stent thrombosis and bleeding in clopidogrel-treated patients: initial evidence of a therapeutic window. J Am Coll Cardiol 56:317–318PubMedCrossRefGoogle Scholar
  6. 6.
    Patti G, Pasceri V, Vizzi V, Ricottini E, Di Sciascio G (2011) Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the antiplatelet therapy for reduction of myocardial damage during angioplasty-bleeding study). Am J Cardiol 107:995–1000PubMedCrossRefGoogle Scholar
  7. 7.
    Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109:3171–3175PubMedCrossRefGoogle Scholar
  8. 8.
    Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750PubMedCrossRefGoogle Scholar
  9. 9.
    Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992–1000PubMedCrossRefGoogle Scholar
  10. 10.
    Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128–1133PubMedCrossRefGoogle Scholar
  11. 11.
    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12 month follow-up. Circulation 119:237–342PubMedCrossRefGoogle Scholar
  12. 12.
    Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856PubMedCrossRefGoogle Scholar
  13. 13.
    Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, Suttorp MJ, Hackeng CM, ten Berg JM (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754–762PubMedCrossRefGoogle Scholar
  14. 14.
    Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, TRITON-TIMI 38 Investigators (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015PubMedCrossRefGoogle Scholar
  15. 15.
    Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, PLATO Investigators, Freij A, Thorsén M (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057PubMedCrossRefGoogle Scholar
  16. 16.
    Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, CURRENT-OASIS 7 Trial Investigators (2010) Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376:1233–1243PubMedCrossRefGoogle Scholar
  17. 17.
    Ferreiro JL, Ueno M, Angiolillo DJ (2009) Cangrelor: a review on its mechanism of action and clinical development. Expert Rev Cardiovasc Ther 7:1195–1201PubMedCrossRefGoogle Scholar
  18. 18.
    Harrington RA, Stone GW, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV Jr, Montalescot G, Mahaffey KW, Kleiman NS, Goodman SG, Amine M, Angiolillo DJ, Becker RC, Chew DP, French WJ, Leisch F, Parikh KH, Skerjanec S, Bhatt DL (2009) Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318–2329PubMedCrossRefGoogle Scholar
  19. 19.
    Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV Jr, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, CHAMPION PLATFORM Investigators (2009) Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330–2341PubMedCrossRefGoogle Scholar
  20. 20.
    Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS (2008) Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527–534PubMedCrossRefGoogle Scholar
  21. 21.
    Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S (2008) The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6:1153–1159PubMedCrossRefGoogle Scholar
  22. 22.
    Schneider DJ, Sobel BE (2009) Streamlining the design of promising clinical trials: in vitro testing of antithrombotic regimens and multiple agonists of platelet activation. Coron Artery Dis 20:175–178PubMedCrossRefGoogle Scholar
  23. 23.
    Jakubowski JA, Li YG, Small DS, Payne CD, Tomlin ME, Luo J, Winters KJ (2010) A comparison of VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol 56:29–37PubMedCrossRefGoogle Scholar
  24. 24.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, TARGET Investigators (2001) Do tirofiban and reopro give similar efficacy trial. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344:1888–1894PubMedCrossRefGoogle Scholar
  25. 25.
    Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ (2002) Suboptimal early inhibition of platelets by treatment with tirofiban: implications for coronary interventions. Am J Cardiol 89:547–550CrossRefGoogle Scholar
  26. 26.
    Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM (1997) Effect of Ca+2 on GP IIb-IIIa interactions with integrelin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 96:1488–1494PubMedCrossRefGoogle Scholar
  27. 27.
    Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Lo M-W, Aggarwal A, Kabbani SS, DiBattiste PM (2003) Association of greater bolus doses with increased concentrations of tirofiban in blood and correlation with the inhibition of platelet aggregation. Am J Cardiol 91:334–336PubMedCrossRefGoogle Scholar
  28. 28.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF (2009) Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120:2577–2585PubMedCrossRefGoogle Scholar
  29. 29.
    Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, Welsby IJ, Voeltz MD, Chandna H, Ramaiah C, Brtko M, Cannon L, Dyke C, Liu T, Montalescot G, Manoukian SV, Prats J, BRIDGE Investigators (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307:265–274PubMedCrossRefGoogle Scholar
  30. 30.
    White HD, Chew DP, Dauerman HL, Mahaffey KW, Gibson CM, Stone GW, Gruberg L, Harrington RA, Bhatt DL (2012) Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 163:182–190PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Dominick J. Angiolillo
    • 1
    Email author
  • David J. Schneider
    • 2
  • Deepak L. Bhatt
    • 3
  • William J. French
    • 4
  • Matthew J. Price
    • 5
  • Jorge F. Saucedo
    • 6
  • Tamaz Shaburishvili
    • 7
  • Kurt Huber
    • 8
  • Jayne Prats
    • 9
  • Tiepu Liu
    • 9
  • Robert A. Harrington
    • 10
  • Richard C. Becker
    • 10
  1. 1.University of Florida College of Medicine-JacksonvilleJacksonvilleUSA
  2. 2.University of VermontBurlingtonUSA
  3. 3.VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical SchoolBostonUSA
  4. 4.Harbor–UCLA Medical CenterTorranceUSA
  5. 5.Division of Cardiovascular Diseases, Scripps ClinicLa JollaUSA
  6. 6.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  7. 7.Diagnostic Services ClinicTbilisiUSA
  8. 8.3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen HospitalViennaAustria
  9. 9.The Medicines CompanyParsippanyUSA
  10. 10.Duke Clinical Research InstituteDuke University Medical CenterDurhamUSA

Personalised recommendations